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We investigated whether treatment with a long-acting b2-agonist (LAb2) is associated with a decrease in patient
compliance with regard to inhalation corticosteroids (ICS).
Date on prescriptions collected by 15 760 patients suffering from airways disease were provided by 69 Dutch
pharmacies. All prescriptions of ICS and LAb2 were analysed and divided in four groups by LAb2 use during 1997
and 1998.
Date from 15 760 patients were available. In the 10 929 patients not treated with LAb2, compliance decreased
slightly but not significantly. In 3281 patients receiving LAb2 compliance also decreased slightly but not
significantly. In 404 patients, who used a LAb2 in 1997 and discontinued treatment in 1998, the compliance fell
significantly (P50?05). In 1147 patients who started to use a LAb2 in 1998, compliance with ICS significantly
improved (P50?05).
These results suggest that the regular use of LAb2 improves compliance with ICS. Therefore, the concern that
compliance with inhaled corticosteroid therapy will decrease under concomitant use of LAb2 appear to be unfounded.
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In the early 1990s, the treatment of asthma and chronic
obstructive pulmonary disease (COPD) significantly chan-
ged following the introduction of the long-acting b2-
agonists (LAb2) salmeterol and formoterol. However,
monotherapy with short-acting as well as long-acting b2-
agonists is not recommended because this may be
associated with a relative under-treatment, and in addition
mask the disease’s underlying inflammatory process (1,2).
International standards (3) only recommend maintenance
treatment with LAb2 in conjunction with inhaled gluco-
corticosteroid (ICS).
The rapid relief of asthma symptoms provided by LAb2
clearly contrasts with the action of ICS. However, as ICS
are now accepted as the foundation for asthma treatment,
the concomitant use of LAb2 with their high subjective
ecacy may jeopardize compliance with ICS usage. This
prompted us to investigate whether the compliance with
ICS will change when a patient concomitantly uses a LAb2.
The hypothesis tested was that after the initiation of the
subjectively strong-acting LAb2 the compliance with ICS
might decrease.Received 25 January 2001 and accepted in revised form 14
February 2001.
Correspondence should be addressed to: Dr R. Aalbers, Depart-
ment of Pulmonology, Martini Hospital (Van Swieten site), Van
Swietenlaan 4, 9728 NZ Groningen, The Netherlands. Fax: +31
(0) 50 5245937.
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Electronic prescription data from 69 pharmacies across The
Netherlands were obtained from patients who collected at
least two prescriptions for an ICS in 1997 and 1998.
Compliance with ICS use was calculated by dividing the
anticipated interval from the prescribed dose and the actual
interval between collecting the subsequent prescriptions.
The population was divided into four groups to compare
compliance with ICS during these 2 years. The first group,
group A, contained the so-called ‘starters’. These patients
did not receive a prescription for LAb2 in 1997 but received
at least one in 1998. The second group, group B (‘never-
users’), contained those patients who never concomitantly
used LAb2 in 1997 and 1998. The third group, group C,
contained patients who are using ICS and LAb2 in 1997 as
well as in 1998. This group is called the ‘ever-users’. The last
group, group D (‘stoppers’), used LAb2 at least once in
1997 but never in 1998. The patients’ characteristics are
presented in Table 1.
STATISTICS
The results of demographics and compliance are expressed
as both mean+ standard deviation (SD) and median values.
The main objective was the compliance of inhaled steroid
use during 1997 and 1998. Data from 1997 were compared
with data from 1998 using a paired Student’s t-test for
normally distributed data (two-tailed) and the Wilcoxon-# 2001 HARCOURT PUBLISHERS LTD
TABLE 1. Demographic data and compliance with ICS and LAb2 use of 15 760 patients, collected in 69 Dutch pharmacies. The
division is by the concomitant LAb2 use during 1997 and/or 1998
Group A (starters) Group B
(never-users)
Group C
(even-user)
Group D
(stoppers)
Number of patients 1146 10 929 3281 404
% male 48?3% 47?9% 52?4% 44?7%
Age (years +SD) 52?1+22?5 43?9+25?8 54?2+21?0 46?8+23?4
Amount of ICS-receipts/patient 1997 2?2 2?6 2?8 2?6
1998 2?6 2?6 2?9 2?5
Receipt duration (days) 1997 74?6 76?5 76?5 77?2
1998 78?0 82?6 79?2 74?4
Daily dosage ICS (mg day71) 1997 791 676 906 812
1998 776 682 900 832
Compliance with ICS (%) 1997 103?1 100?0 104?7 109?9
1998 106?4* 98?9 102?0 102?0*
Compliance with LAb2 (%) 1997 – – 102?0 94?5
1998 101?2 – 100?0 –
ICS: inhalation glucocorticosteroid; LAb2: long-acting b2-agonist.
For almost all data: mean value+standard deviation (SD), for compliance median values.*P50?05, t-test.
LONG -ACTING b2-AGONISTS IMPROVE COMPLIANCE WITH ICS 405rank test for non-normally distributed data. A P-value less
than 0?05 was considered significant.
Results
Data from 15 760 patients were available, divided into four
groups by their LAb2 use during 1997 and/or 1998 as
shown in Table 1. No great dissimilarities between the
groups were observed.
The prescribed medication, the expected and real interval
between two ICS prescriptions, as well as calculated
compliance, are shown in Table 1. Multiple inhalers could
be prescribed on one receipt. The median compliance with
ICS is presented in Fig. 1, and is remarkably high in all four
groups (close to 100%). The compliance decreased in three
groups from 1997 to 1998 whereas in group A, patients who
started to use LAb2 on top of their ICS, compliance for ICS
increased. In groups A and D, changes in compliance are
statistically significant (P50?05). In groups B and C no
change in compliance was observed. The compliance for
LAb2 in 1997 and 1998 are similar (Table 1).
The daily dosage of ICS remained stable during the
observed period. The dosage of ICS was highest in group C,
the patients who used a LAb2 in 1997 and 1998. The lowest
dose of ICS was used by the patients in group B, the never-
users. In groups A and D the daily dosage of ICS did not
significantly increase.
Discussion
We tested the hypothesis that after the initiation of the
subjectively strong-acting LAb2 the compliance with ICS
may decrease. However, compliance with ICS improvedsignificantly after the start of LAb2 and attenuated if the
LAb2 was stopped. In the groups without concomitant
LAb2 use or with continuation of use of LAb2, compliance
with ICS remained the same.
A probable explanation for the present findings is that
compliance with ICS is boosted by the highly subjective
ecacy of the LAb2. The effect of LAb2 is easily recognized
by patients, and gives an improvement of the lung function
and relief of symptoms within days in contrast to the effects
of ICS, which are only measurable after weeks and may go
unnoticed by the patient. As these effects are not easily
recognized by patients, compliance with the medication
may be hindered. It could be that the patient’s trust in the
ecacy of prescribed medication may improve, if a
subjectively strong-working medication is combined with
a subjectively less effective medication. However, this idea
has never been proved.
In this study prescription data of delivered medication
from a large group of patients who received at least two
prescriptions for ICS are analysed. This excludes patients
with poor compliance, patients who only need medication
for a short period (for example patients suffering from
seasonal asthma) and patients who do not fetch their
prescribed medication [about 10% of the population (4)].
From the latter group one may doubt if this would have
influenced the results of this study: because if patients are
not willing to fetch their prescribed medication, the
addition of long-acting b2-agonists will presumably not
alter the compliance of inhaled steroids.
However, although a correct timing of prescription
renewal is suggestive for correct adherence to prescribed
treatment, this is not certain. In clinical trials, for instance,
about one in three of the patients ‘cheats’ in this way (5).
Indeed, during a clinical trial patients are aware of being
observed which may induce sociably desired behaviour and
FIG. 1. Compliance (%, median value) with inhaled glucocrticosteroid therapy. Group A: started with the use of LAb2 in 1998
(n=1446); group B: no concomitant use of LAb2 in both 1997 and 1998 (n=10 929); group C: in both years concomitant
LAb2 use (n=3281); group D: the concomitant use of LAb2 is stopped in 1998 (n=404). *P50?05. 1997 (open bars), 1998
(solid bars).
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patients were unaware of being observed leading to a more
natural pattern of behaviour.
Several other methods are available for measuring
compliance, such as biochemical measures, clinical judge-
ment, self-report, asthma diaries and medication monitors.
These methods may be more accurate but have other
disadvantages which limit their use on a large scale.
Biochemical measures are invasive, expensive and provide
no information about usage patterns over time (6). Clinical
judgement had a low validity and reliability (6). Self-report
and diaries have a highly variable validity (6). Diaries are
vulnerable to patients’ deceit (6). Medication monitors are
expensive and patients can react to the presence of a
monitoring device.
Examining pharmacy records of dispensing patterns is
regarded as useful for measuring compliance with long-
term medication regimens (6) and has proven to be useful in
investigating trends or hypotheses (7). It is an unobtrusive
method, as neither the patients nor the physicians are aware
of the registration process. Accordingly there is no
interference with the natural patterns of medication use
and the bias within the study is therefore reduced. It
provides only a course estimation of compliance and
probably over-estimates it, since neither the return of
medication nor the daily pattern of medication use and
adherence is monitored (6). Thus, this methods is valid for
examining trends in patients using chronically ICS and
LAb2 and the present study is unique with respect to the
large number of patients (25 000). According to this study,
the concomittant use of LAb2 does not decrease compliance
in patients who chronically use ICS.
The results of this study are confirmed by a recent using
prescribed data instead of delivered medication (4). An
increase in compliance with ICS from 90% to 103% on theaddition of LAb2 was observed. Also, in other studies the
addition of salmeterol (8) or short-acting b2 (9) did not
adversely affect compliance with inhaled corticosteroid
therapy (7).
A remarkable finding of our study is that physicians,
until now, do not lower the dose of ICS when additional
LAb2 is prescribed. This is in contrast to the recently
published studies which show that adding LAb2 to ICS
therapy is as effective or even more effective than increasing
the ICS dose two- to four-fold (10–12).
In summary, the results of our study show no decrease in
compliance with ICS when LAb2 is added in patients who
chronically use inhaled corticosteroids. On the contrary,
LAb2 improves compliance with ICS.
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